Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Ptc Therapeutics (PTCT) Accumulated Depreciation & Amortization (2016 - 2025)

Ptc Therapeutics has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $47.0 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $47.0 million for Q4 2025, up 40.87% from a year ago — trailing twelve months through Dec 2025 was $47.0 million (up 40.87% YoY), and the annual figure for FY2025 was $47.0 million, up 40.87%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $47.0 million at Ptc Therapeutics, up from $33.4 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for PTCT hit a ceiling of $51.3 million in Q4 2023 and a floor of $27.2 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $37.4 million (2022), compared with a mean of $39.2 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: soared 50.44% in 2021 and later crashed 34.94% in 2024.
  • Ptc Therapeutics' Accumulated Depreciation & Amortization stood at $27.2 million in 2021, then skyrocketed by 37.52% to $37.4 million in 2022, then soared by 37.21% to $51.3 million in 2023, then crashed by 34.94% to $33.4 million in 2024, then surged by 40.87% to $47.0 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $47.0 million (Q4 2025), $33.4 million (Q4 2024), and $51.3 million (Q4 2023) per Business Quant data.